SEC Company Response from NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Nov 1, 2019
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: Nov. 1, 2019 · CIK: 0001389545 · Accession: 0001437749-19-021135
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234330
Letter
Re:
nby20191031_corresp.htm
November 1, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
NovaBay Pharmaceuticals, Inc. (the “Company”)
Form S-1, File No. 333-234330
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective as of 5:00 p.m. (Eastern time) on Tuesday, November 5, 2019, or as soon as practicable thereafter.
Very truly yours,
NovaBay Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm nby20191031_corresp.htm November 1, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: NovaBay Pharmaceuticals, Inc. (the “Company”) Form S-1, File No. 333-234330 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective as of 5:00 p.m. (Eastern time) on Tuesday, November 5, 2019, or as soon as practicable thereafter. Very truly yours, NovaBay Pharmaceuticals, Inc. By: /s/ Justin Hall Justin Hall President & Chief Executive Officer and General Counsel cc: Abby E. Brown, Squire Patton Boggs (US) LLP